المؤلفون: К. Лактионов К., Е. Артамонова В., В. Бредер В., В. Горбунова А., Ф. Моисеенко В., Е. Реутова В., Д. Сакаева Д., А. Смолин В., М. Тер-Ованесов Д.

المصدر: Malignant tumours; Том 11, № 3s2-1 (2021); 36-54 ; Злокачественные опухоли; Том 11, № 3s2-1 (2021); 36-54 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: немелкоклеточный рак легкого, аденокарцинома, неплоскоклеточный рак легкого, плоскоклеточный рак легкого, мутация EGFR, транслокация ALK, ROS1

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/851/599; https://www.malignanttumors.org/jour/article/view/851

الاتاحة: https://www.malignanttumors.org/jour/article/view/851
https://doi.org/10.18027/2224-5057-2021-11-3s2-02

المؤلفون: K. Sarantseva A., K. Laktionov K., E. Reutova V., D. Yudin I., V. Breder V., К. Саранцева А., К. Лактионов К., Е. Реутова В., Д. Юдин И., В. Бредер В.

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2020); 194-198 ; Медицинский Совет; № 20 (2020); 194-198 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: EGFR tyrosine kinase inhibitors, osimertinib, metastases, brain, lung cancer, non-small cell lung cancer, ингибиторы тирозинкиназы EGFR, осимертиниб, метастазы, головной мозг, рак легкого, немелкоклеточный рак легкого

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5956/5436; Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874. doi:10.1200/JCO.2010.33.4235.; Zhou C., Wu Y.L., Chen G., Feng J., Liu X.-Q., Wang C. et al. Erlotinib versus chemotherapy as first‐line treatment for patients with advanced EGFR mutation‐positive non‐small‐cell lung cancer (OPTIMAL, CTONG‐0802): a multicentre, open‐label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X.; Реутова Е.В., Лактионов К.П., Юдин Д.И., Нелюбина Л.А., Горохова Г.К., Егорова А.В. Осимертиниб в 1-й линии терапии EGFR-позитивного немелкоклеточного рака легкого. Современная онкология. 2019;21(3):17–20. doi:10.26442/18151434.2019.3.190659.; Mok T.S., Wu Y.-L., Ahn M.-J., Garassino M.C., Kim H.R., Ramalingam S.S. et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa1612674.; Soria J.C., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee K.H. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa1713137.; Ramalingam S.S., Vansteenkiste J., Planchard D., Cho B.C., Gray J.E., Ohe Y. et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa1913662.; Suda K., Mizuuchi H., Maehara Y., Mitsudomi T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation – diversity, ductility, and destiny. Cancer Metastasis Rev. 2012;31(3–4):807–814. doi:10.1007/s10555-012-9391-7.pub4.; Sharma S.V., Bell D.W., Settleman J., Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc2088.; Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W. et al. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib. NEJM. 2004;350(21):2129–2139. doi:10.1056/NEJMoa040938.; Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500. doi:10.1126/science.1099314.; Cheng L., Alexander R.E., Maclennan G.T., Cummings O.W., Montironi R., LopezBeltran A. et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25(3):347–369. doi:10.1038/modpathol.2011.215.; Tjulandin S., Imyanitov E., Moiseyenko V., Ponomarenko D., Gurina L., Koroleva I., Karaseva V. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung. Curr Med Res Opin. 2015;31(6):1117–1127. doi:10.1185/03007995.2015.1036015.; Planchard D., Popat S., Kerr K., Novello S., Smit E.F., Faivre-Finn C. et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(4 Suppl.):iv192–iv237. doi:10.1093/annonc/mdy275.; Ballard P., Yates J.W., Yang Z., Kim D.W., Yang J.C., Cantarini M. et al. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016;22(20):5130–5140. doi:10.1158/1078-0432.CCR-16-0399.; Togashi Y., Masago K., Masuda S., Mizuno T., Fukudo M., Ikemi Y. et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70:399–405. doi:10.1007/s00280-012-1929-4.; Hoffknecht P., Tufman A., Wehler T., Pelzer T., Wiewrodt R., Schütz M. et al. Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-smallcell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2015;10(1):156–163. doi:10.1097/JTO.0000000000000380.; Batra U., Lokeshwar N., Gupta S., Shirsath P. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients. Indian J Cancer. 2017;54(Suppl.):S37–S44. doi:10.4103/ijc.IJC_532_17.; Park S.J., Kim H.T., Lee D.H., Kim K.P., Kim S.W., Suh C., Lee J.S. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer. 2012;77(3):556–560. doi:10.1016/j.lungcan.2012.05.092.; Lee Y.J., Choi H.J., Kim S.K., Chang J., Moon J.W., Park I.K. et al. Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall cell lung cancer. Cancer. 2010;116(5):1336–1343. doi:10.1002/cncr.24877.; Peters S., Bexelius C., Munk V., Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–162. doi:10.1016/j.ctrv.2016.03.009.; Goss G., Tsai C.M., Shepherd F.A., Ahn M.J., Bazhenova L., Crinò L. et al. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. Ann Oncol. 2018;29(3):687–693. doi:10.1093/annonc/mdx820.; Wu Y.L., Ahn M.J., Garassino M.C., Han J.Y., Katakami N., Kim H.R. et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced NonSmall-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018;36(26):2702–2709. doi:10.1200/JCO.2018.77.9363.; Yang J.C., Ahn M.J., Kim D.W., Ramalingam S.S., Sequist L.V., Su W.C. et al. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017;35(12):1288–1296. doi:10.1200/JCO.2016.70.3223.; Goss G., Tsai C.M., Shepherd F.A., Bazhenova L., Lee J.S., Chang G.C. et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-smallcell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643–1652. doi:10.1016/S1470-2045(16)30508-3.; Reungwetwattana T., Nakagawa K., Cho B.C., Cobo M., Cho E.K., Bertolini A. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with Untreated EGFRMutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36(33):3290–3297. doi:10.1200/JCO.2018.78.3118.; Lee S.J., Lee J.I., Nam D.H., Ahn Y.C., Han J.H., Sun J.M. et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013;8(2):185–191. doi:10.1097/JTO.0b013e3182773f21.; https://www.med-sovet.pro/jour/article/view/5956

الاتاحة: https://www.med-sovet.pro/jour/article/view/5956
https://doi.org/10.21518/2079-701X-2020-20-194-198

المؤلفون: E. Reutova V., L. Laktionova V., D. Marinov T., D. Peregudov A., T. Borisova N., Е. Реутова В., Л. Лактионова В., Д. Маринов Т., Д. Перегудов А., Т. Борисова Н.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 176-181 ; Медицинский Совет; № 9 (2020); 176-181 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: ALK translocation, non-small cell lung cancer, targeted therapy, crizotinib, транслокация ALK, немелкоклеточный рак легкого, таргетная терапия, кризотинибтранслокация ALK, кризотиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5721/5219; Sahu A., Prabhash K., Noronha V., Joshi A., Desai S. Crizotinib: A comprehensive review. South Asian J Cancer. 2013;2(2):91–97. doi:10.4103/2278-330X.110506.; Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T. et al. Firstline crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. doi:10.1056/NEJMoa1408440.; Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.-J. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. doi:10.1056/NEJMoa1214886. Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Моисеенко Ф.В., Реутова Е.В. и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Злокачественные опухоли. 2019;9(3s2):32–48. Режим доступа: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf. Laktionov K.K., Artamonova E.V., Breder V.V., Gorbunova V.A., Moiseenko F.V., Reutova E.V. et al. Practical guidelines for the medicinal treatment of non-small cell cancer. Zlokachestvennye opukholi = Malignant Tumours. 2019;9(3s2):2–48. (In Russ.) Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-01.pdf.; Demidova I., Grinevich V., Avdalian A., Imyanitov E., Gikalo М., Savelov et al. Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches Lung Cancer. 2017;103:17–23. 10.1016/j.lungcan.2016.11.001.; Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. SOJ Thoracic Oncology. 2009;4(12):1450–1454. doi:10.1097/JTO.0b013e3181c4dedb.; Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S. et al. Identification of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature. 2007;448(7153):561–566. doi:10.1038/nature05945.; Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253. doi:10.1200/JCO.2009.22.6993.; Демидова И.А., Цепенщикова Е.О., Баринов А.А., Гагарин И.М., Савелов Н.А., Гриневич В.Н., Тюляндин С.А. Определение перестроек гена ALK в селектированной популяции российских больных немелкоклеточным раком легкого. Злокачественные опухоли. 2013;3(7):3–9. doi:10.18027/2224-5057-2013-3-3-9. Demidova I.A., Tepenshchikova E.O., Barinov А.А., Gagarin I.M., Savelov N.A., Grinevich V.N., Tulyandin S.A. Determination of ALK gene rearrangements in a selected population of Russian patients with non-small cell lung cancer. Zlokachestvennye opukholi = Malignant Tumours. 2013;3(7):3–9. (In Russ.) doi:10.18027/2224-5057-2013-3-3-9.; Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B. et al. Activity and safety of crizotinib in patients with ALK-positive non-smallcell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13(10):1011–1019. doi:10.1016/S1470-2045(12)70344-3.; Blackhall F., Ross Camidge D., Shaw A.T., Soria J.C., Solomon B.J., Mok T. et al. Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. ESMO Open. 2017;2(3):e000219. doi:10.1136/esmoopen-2017-000219.; Shaw A.T., Kim T.M., Crinò L., Gridelli C., Kiura K., Liu G. et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(7):874–886. doi:10.1016/S1470-2045(17)30339-X.; Novello S., Mazières J., Oh I.J., de Castro J., Migliorino M. R., Helland Å. et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018;29(6):1409–1416. doi:10.1093/annonc/mdy121.; Huber R.M., Hansen K.H., Paz-Ares Rodriguez L., West H.L., Reckamp K.L., Leighl N.B. et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. J Thorac Oncol. 2020;15(3):404–415. doi:10.1016/j.jtho.2019.11.004.; Solomon B.J., Besse B., Bauer T.M., Felip E., Soo R.A., Camidge D.R. et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654– 1667. doi:10.1016/S1470-2045(18)30649-1.; Rangachari D., Le X., Shea M., Huberman M. S., Van der Laan P.A., Kobayashi S.S., Costa D.B. Cases of ALK-Rearranged Lung Cancer with 5-Year ProgressionFree Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017;12(11):e175-e177. doi:10.1016/j.jtho.2017.06.002.; Solomon B.J., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., Felip E. et al. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794.; Duruisseaux M., Besse B., Cadranel J., Pérol M., Mennecier B., Bigay-Game L. et al. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8(13):21903– 21917. doi:10.18632/oncotarget.15746.; Peters S., Camidge D.R., Shaw A.T., Gadgeel S., Ahn J.S., Kim D.W. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377:829–838. doi:10.1056/NEJMoa1704795.; Sakakibara-Konishi J., Kitai H., Ikezawa Y., Hatanaka Y., Sasaki T., Yoshida R. et al. Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non-small-cell Lung Cancer. Clinical Lung Cancer. 2019;20(5):e555-e559. doi:10.1016/j.cllc.2019.06.021.; Shaw A.T., Friboulet L., Leshchiner I., Gainor J.F., Bergqvist S., Brooun A. et al. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. N Engl J Med. 2016;374(1):54–61. doi:10.1056/NEJMoa1508887.; https://www.med-sovet.pro/jour/article/view/5721

الاتاحة: https://www.med-sovet.pro/jour/article/view/5721
https://doi.org/10.21518/2079-701X-2020-9-176-181

المؤلفون: A. Kuzminov E., T. Borisova N., V. Breder V., E. Reutova V., T. Barbolina D., K. Laktionov K., А. Кузьминов Е., Т. Борисова Н., В. Бредер В., Е. Реутова В., Т. Барболина Д., К. Лактионов К.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 190-195 ; Медицинский Совет; № 9 (2020); 190-195 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: localized small cell lung cancer, prophylactic brain irradiation, early chemoradiotherapy, late chemoradiotherapy, simultaneous chemoradiotherapy, consecutive chemoradiotherapy, локализованный мелкоклеточный рак легкого, профилактическое облучение головного мозга, ранняя химиолучевая терапия, поздняя химиолучевая терапия, одновременная химиолучевая терапия, последовательная химиолучевая терапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5735/5233; Warde P., Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890–895. doi:10.1200/JCO.1992.10.6.890.; Pignon J.P., Arriagada R., Ihde D.C., Johnson D.H., Perry M.C., Souhami R.L. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618–1624. doi:10.1056/NEJM199212033272302.; Fried D.B., Morris D.E., Poole C., Rosenman J.G., Halle J.S., Detterbeck F.C. et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004;22(23):4837–4845. doi:10.1200/JCO.2004.01.178.; Stinchcombe T.E., Gore E.M. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187–195. doi:10.1634/theoncologist.2009-0298.; Murray N., Coy P., Pater J.L., Hodson I., Arnold A., Zee B.C. et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11(2):336–344. doi:10.1200/JCO.1993.11.2.336.; Pijls-Johannesma M., De Ruysscher D., Vansteenkiste J., Kester A., Rutten I., Lambin P. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev. 2007;33(5):461–473. doi:10.1016/j.ctrv.2007.03.002.; Spiro S.G., James L.E., Rudd R.M., Trask C.W., Tobias J.S., Snee M. et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. J Clin Oncol. 2006;24(24):3823–3830. doi:10.1200/JCO.2005.05.3181.; Schild S.E., Bonner J.A., Shanahan T.G., Brooks B.J., Marks R.S., Geyer S.M. et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;59(4):943–951. doi:10.1016/j.ijrobp.2004.01.055.; De Ruysscher D., Lueza B., Le Péchoux C., Johnson D.H., O’Brien M., Murray N. et al. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. Ann Oncol. 2016;27(10):1818–1828. doi:10.1093/annonc/mdw263.; De Ruysscher D., Pijls-Johannesma M., Bentzen S.M., Minken A., Wanders R., Lutgens L. et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006;24(7):1057–1063. doi:10.1200/JCO.2005.02.9793.; Bonner J.A., Sloan J.A., Shanahan T.G., Brooks B.J., Marks R.S., Krook J.E. et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol. 1999;17(9):2681–2681. doi:10.1200/JCO.1999.17.9.2681.; Kies M.S., Mira J.G., Crowley J.J., Chen T.T., Pazdur R., Grozea P.N. et al. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reducedfield radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol. 1987;5(4):592–600. doi:10.1200/JCO.1987.5.4.592.; Turrisi A.T., Kim K., Blum R., Sause W.T., Livingston R.B., Komaki R. et al. Twice-daily compared with once-daily thoracic radiotherapy in limited smallcell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–271. doi:10.1056/NEJM199901283400403.; Faivre-Finn C., Snee M., Ashcroft L., Ashcroft L., Appel W., Barlesi F. et al. Concurrent Once-Daily Versus Twice-Daily Chemoradiotherapy in Patients With Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3, Randomised, Superiority Trial Lancet Oncol. 2017;18(8):1116– 1125. doi:10.1016/S1470-2045(17)30318-2.; Arriagada R., Le Chevalier T., Borie F., Rivière A., Chomy P., Monnet I. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst. 1995;87(3):183–190. doi:10.1093/jnci/87.3.183.; Aupérin A., Arriagada R., Pignon J.P., Le Péchoux С., Gregor A., Stephens R.J. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341(7):476–484. doi:10.1056/NEJM199908123410703.; Wolfson A.H., Bae K., Komaki R., Meyers С., Movsas В., Le Pechoux С. et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84. doi:10.1016/j.ijrobp.2010.05.013.; Zhang W., Jiang W., Luan L., Wang L., Zheng X., Wang G. Prophylactic cranial irradiation for patients with small-cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2014;14:793. doi:10.1186/1471-2407-14-793.; Sun A., Bae K., Gore E.M., Movsas B., Wong S.J., Meyers C.A., Bonner J.A. et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non–small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol. 2010;29(3):279– 286. doi:10.1200/JCO.2010.29.6053.; Gondi V., Paulus R., Bruner D.W., Meyers C.A., Gore E.M., Wolfson A. et al. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys. 2013;86(4):656–664. doi:10.1016/j.ijrobp.2013.02.033.; Le Péchoux C., Dunant A., Senan S., Wolfson A., Quoix E., Faivre-Finn C. et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003- 08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol. 2009;10(5):467–474. doi:10.1016/S1470-2045(09)70101-9.; https://www.med-sovet.pro/jour/article/view/5735

الاتاحة: https://www.med-sovet.pro/jour/article/view/5735
https://doi.org/10.21518/2079-701X-2020-9-190-195

المؤلفون: D. Yudin I., K. Laktionov K., K. Sarantseva A., O. Borisova I., V. Breder V., E. Reutova V., M. Beloyartseva F., S. Kruteleva Yu., I. Dzhanyan A., Д. Юдин И., К. Лактионов К., К. Саранцева А., О. Борисова И., В. Бредер В., Е. Реутова В., М. Белоярцева Ф., С. Крутелева Ю., И. Джанян А.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2020); 16-24 ; Медицинский Совет; № 9 (2020); 16-24 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: immune-related endocrinopathy, immunotherapy, checkpoint inhibitors, anti-CTLA-4, anti-PD-1/PD-L1, иммуноопосредованная эндокринопатия, иммунотерапия, ингибиторы контрольных точек, анти-CTLA-4, анти-PD-1/PD-L1

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5697/5195; Horn L., Gettinger S.N., Gordon M.S., Herbst R.S., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. Eur J Cancer. 2018;101:201–209. doi:10.1016/j.ejca.2018.06.031.; Antonia S.J., Borghaei H., Ramalingam S.S., Horn L., de Castro Carpeño J., Pluzanski A. et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408. doi:10.1016/S1470-2045(19)30407-3.; Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M. et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced NonSmall-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol. 2018;36(17):1675–1684. doi:10.1200/JCO.2017.77.0412.; Fogt S., Shustova M., Demidov L.V., Moiseyenko V., Tjulandin S., Semiglazova T. et al. Phase II trial (BCD-100-2/MIRACULUM) of the novel PD-1 inhibitor (BCD-100) in patients with advanced melanoma. J Clin Oncol. 2019;37(15):9549. doi:10.1200/JCO.2019.37.15_suppl.9549.; Vaishampayan U., Schöffski P., Ravaud A., Borel C., Peguero J., Chaves J. et al. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):275. doi:10.1186/s40425-019-0746-2.; Tan M.H., Iyengar R., Mizokami-Stout K., Yentz S., MacEachern M.P., Shen L.Y. et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5:1. doi:10.1186/s40842-018-0073-4.; Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.; Weber J., Mandala M., del Vecchio M., Gogas H.J., Arance A.M., Cowey C.L. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824–1835. doi:10.1056/NEJMoa1709030.; Garon E.B., Hellmann M.D., Rizvi N.A., Carcereny E., Leighl N.B., Ahn M.J. et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol. 2019;37(28):2518–2527. doi:10.1200/JCO.19.00934.; Hellmann M.D., Ciuleanu T.-E., Pluzanski A., Lee J.S., Otterson G.A., AudigierValette C. et al. Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018;378(22):2093–2104. doi:10.1056/NEJMoa1801946.; Mok T.S.K., Wu Y.L., Kudaba I., Kowalski D.M., Cho B.C., Turna H.Z. et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1- expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi: doi:10.1016/S0140-6736(18)32409-7.; Socinski M.A., Jotte R.M., Cappuzzo F., Orlandi F., Stroyakovskiy D., Nogami N. et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948.; Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R. et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937.; Morganstein D.L., Lai Z., Spain L., Diem S., Levine D., Mace C. et al. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin Endocrinol (Oxf). 2017;86(4):614–620. doi:10.1111/cen.13297.; Robert C., Joshua A.M., Kefford R., Joseph R.W., Wolchok J.D., Hodi F.S. et al. Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001. Journal of Clinical Oncology. 2015;33(15):9050. doi:10.1200/jco.2015.33.15_suppl.9050.; McMillen B., Dhillon M.S., Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep. 2016;2016:10.1136/bcr-214603. doi:10.1136/bcr-2016-214603.; Win M.A., Thein K.Z., Qdaisat A., Yeung S.J. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. Am J Emerg Med. 2017;35(7):1039.e5–1039.e7. doi:10.1016/j.ajem.2017.02.048.; Trinh B., Sanchez G.O., Herzig P., Läubli H. Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. J Immunother Cancer. 2019;7(1):52. doi:10.1186/s40425-019-0528-x.; Barroso-Sousa R., Barry W.T., Garrido-Castro A.C., Hodi F.S., Min L., Krop I.E., Tolaney S.M. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Metaanalysis. JAMA Oncol. 2018;4(2):173–182. doi:10.1001/jamaoncol.2017.3064.; Paepegaey A.C., Lheure C., Ratour C., Lethielleux G., Clerc J., Bertherat J. et al. Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. J Endocr Soc. 2017;1(6):646–649. doi:10.1210/js.2017-00170.; Dillard T., Yedinak C.G., Alumkal J., Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13(1):29–38. doi:10.1007/s11102-009-0193-z.; Torino F., Barnabei A., De Vecchis L., Salvatori R., Corsello S.M. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist. 2012;17(4):525–535. doi:10.1634/theoncologist.2011-0404.; Corsello S.M., Barnabei A., Marchetti P., De Vecchis L., Salvatori R., Torino F. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab. 2013;98(4):1361–1375. doi:10.1210/jc.2012-4075.; Blansfield J.A., Beck K.E., Tran K., Yang J.C., Hughes M.S., Kammula U.S. et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005;28(6):593–598. doi:10.1097/01. cji.0000178913.41256.06.; Albarel F., Gaudy C., Castinetti F., Carré T., Morange I., Conte-Devolx B. et al. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol. 2015;172(2):195–204. doi:10.1530/EJE-14-0845.; Min L., Hodi F.S., Giobbie-Hurder A., Ott P.A., Luke J.J., Donahue H. et al. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: A retrospective cohort study. Clin Cancer Res. 2015;21(4):749–755. doi:10.1158/1078-0432.CCR-14-2353.; Zhao C., Tella S.H., Del Rivero J., Kommalapati A., Ebenuwa I., Gulley J. et al. Anti-PD-L1 Treatment Induced Central Diabetes Insipidus. J Clin Endocrinol Metab. 2018;103(2):365–369. doi:10.1210/jc.2017-01905.; Barroso-Sousa R., Ott P.A., Hodi F.S., Kaiser U.B., Tolaney S.M., Min L. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer. 2018;124(6):1111–1121. doi:10.1002/cncr.31200.; Clotman K., Janssens K., Specenier P., Weets I., De Block C.E.M. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103(9):3144–3154. doi:10.1210/jc.2018-00728.; Shamy T.A., Aguasvivas M., Serhan M., Fojas M.M. Diabetic Ketoacidosis Triggered by Pembrolizumab in a Patient with Bladder Cancer. Diabetes. 2018;67(1):219–LB. doi:10.2337/db18-219-LB.; Maamari J., Yeung S.J., Chaftari P.S. Diabetic ketoacidosis induced by a single dose of pembrolizumab. Am J Emerg Med. 2019;37(2):376.e1–376.e2. doi:10.1016/j.ajem.2018.10.040.; https://www.med-sovet.pro/jour/article/view/5697

الاتاحة: https://www.med-sovet.pro/jour/article/view/5697
https://doi.org/10.21518/2079-701X-2020-9-16-24

المؤلفون: K. Laktionov K., K. Sarantseva A., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., К. Лактионов К., К. Саранцева А., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 16-21 ; Медицинский Совет; № 19 (2019); 16-21 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: immunotherapy, non-small cell lung cancer, checkpoint inhibitors, nivolumab, иммунотерапия, немелкоклеточный рак легкого, ингибиторы контрольных точек, ниволумаб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5036/4585; Gettinger S., Horn L., Jackman D. at al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study. Journal of Clinical Oncology 2018;36(17):JCO2017770412.·doi:10.1200/JCO.2017.77.0412.; Horn L., Spigel D.R., Vokes E.E., Holgado E., Ready N., Steins M. et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: TwoYear Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). J Clin Oncol. 2017;35(35):3924-3933. doi:. 10.1200/JCO.2017.74.3062; Reck M., Taylor F., Penrod J.R., DeRosa M., Morrissey L., Dastani H., Orsini L., Gralla R.J. Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non–Small Cell Lung Cancer: Results from the CheckMate 017 Study. J Thorac Oncol. 201813(2):194-204. doi:10.1016/j.jtho.2017.10.029.; Лактионов К.К., Саранцева К.А., Бредер В.В., Реутова Е.В., Юдин Д.И., Лактионова Л.В. Результаты применения ниволумаба у больных с немелкоклеточным раком легкого в клинической практике. Вопросы онкологии. 2017;63(5):724-728.; Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2016;(3):17-24. doi:10.18027/2224-5057-2016-3-17-24.; Burstein H.J., Krilov L., Aragon-Ching J.B., Baxter N.N., Chiorean E.G., Chow W.A. et al. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017;35(12):1341-1367. doi:10.1200/JCO.2016.71.5292.; Chae Y.K., Pan A., Davis A.A., Raparia K., Mohindra N.A., Matsangou M., Giles F.J. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cacer:Is PD-L1 Expression a Good Marker for Patient Selection? Clin Lung Cancer. 2016;17(5):350-361. doi:10.1016/j.cllc.2016.03.011.; https://www.med-sovet.pro/jour/article/view/5036

الاتاحة: https://www.med-sovet.pro/jour/article/view/5036
https://doi.org/10.21518/2079-701X-2019-19-16-21

المؤلفون: K. Laktionov K., D. Yudin I., V. Breder V., E. Reutova V., K. Laktionov P., D. Marinov T., D. Peregudov A., M. Ardzinba S., К. Лактионов К., Д. Юдин И., В. Бредер В., Е. Реутова В., К. Лактионов П., Д. Маринов Т., Д. Перегудов А., М. Ардзинба С.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2019); 110-114 ; Медицинский Совет; № 10 (2019); 110-114 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-10

مصطلحات موضوعية: NSCLC, EGFR, tyrosine kinase inhibitors, integrated chemotherapy, НМРЛ, ингибиторы тирозинкиназы, интегрированная химиотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3060/2984; Rosell R., Carcereny E., Gervais R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012;13(3):239-246.; Sequist L.V., Yang J.C., Yamamoto N. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-3334.; Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-957.; Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis. PLOS ONE. 2013 November 8;8(Issue 11):e79000. www.plosone.org; Kanda S., Horinouchi H., Fujiwara Y., Nokihara H., Yamamoto N., Sekine I., Kunitoh H., Kubota K., Tamura T., Ohe Y. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy. Lung Cancer. 2015 Sep;89(3):287-93.; Soria J.-C., Ohe Y., Vansteenkiste J. et al. FLAURA Investigators. Osimertinib in untreated EGFRmutated advanced non-small-cell lung cancer. N Engl J Med. 2018;278(2):113-125.; Bean J., Brennan C., Shih J.Y., Riely G., Viale A., Wang L. et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 2007;104:20932–20937.; Engleman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O. et al. MET amplification leads to gefitinib resistance in lung cancer by activation ERBB3 signaling. Science. 2007;316:1039–1043.; Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247.; Soria J.C., Wu Y.L., Nakagawa K. et al. Gefi tinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-smallcell lung cancer after progression on first-line gefi tinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16:990–98.; Saito H., Fukuhara T. et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous nonsmall- cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20:625–35.; Nakamura A., Inoue A. et al. Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). Journal of Clinical Oncology. 2018 May 20;36(15_suppl):9005-9005.; https://www.med-sovet.pro/jour/article/view/3060

الاتاحة: https://www.med-sovet.pro/jour/article/view/3060
https://doi.org/10.21518/2079-701X-2019-10-110-114

المؤلفون: K. Laktionov K., V. Breder V., D. Yudin I., K. Sarantseva A., L. Laktionova V., M. Ardzinba S., E. Reutova V., A. Egorova V., К. Лактионов К., В. Бредер В., Д. Юдин И., К. Саранцева А., Л. Лактионова В., М. Ардзинба С., Е. Реутова В., А. Егорова В.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 22-29 ; Медицинский Совет; № 19 (2019); 22-29 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: neoadjuvant immunotherapy, non-small cell lung cancer, checkpoint inhibitors, неоадъювантная иммунотерапия, немелкоклеточный рак легкого, ингибиторы контрольных точек

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5047/4596; Eberhardt W.E., Mitchell A., Crowley J., Kondo H., Kim Y.T., Turrisi A. 3rd, Goldstraw P., RamiPorta R. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2015;10(11):1515-22. doi:10.1097/JTO.0000000000000673.; Asamura H., Chansky K., Crowley J., Goldstraw P., Rusch V.W., Vansteenkiste J., et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):1675–1684. doi:10.1097/JTO.0000000000000678.; Rami-Porta R., Bolejack V., Crowley J., Ball D., Kim J., Lyons G., et al. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;(10):990–1003. doi:10.1097/JTO.0000000000000559.; Hilaris B.S., Gomez J., Nori D., Anderson L.L., Martini N. Combined surgery, intraoperative brachytherapy, and postoperative external radiation in stage III non-small cell lung cancer. Cancer. 1985;(55):1226–1231. doi:10.1002/1097-0142(19850315)55:63.0.co;2-6.; Faber L.P., Kittle C.F., Warren W.H., Bonomi P.D., Taylor S.G. 4th, Reddy S., Lee M.S. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg. 1989;(47):669–675; discussion 676-667. doi:10.1016/0003-4975(89)90115-x.; Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Cantó A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;(330):153–158. doi:10.1056/NEJM199401203300301.; Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam J.B. Jr., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non–small-cell lung cancer. J Natl Cancer Inst. 1994;(86):673–680. doi:10.1093/jnci/86.9.673.; Pisters K.M., Vallieres E., Crowley J.J., Franklin W.A., Bunn P.A. Jr, Ginsberg R.J., Putnam J.B. Jr., Chansky K., Gandara D. Surgery with or without preoperative paclitaxel and carboplatin in earlystage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol. 2010;(28):1843–1849. doi:10.1200/JCO.2009.26.1685.; Felip E., Rosell R., Maestre J.A., RodríguezPaniagua J.M., Morán T., Astudillo J., Alonso G. et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-smallcell lung cancer. J Clin Oncol. 2010;(28):3138–3145. doi:10.1200/JCO.2009.27.6204.; Scagliotti G.V., Pastorino U., Vansteenkiste J.F., Spaggiari L., Facciolo F., Orlowski T.M., et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non–smallcell lung cancer. J Clin Oncol. 2012;(30):172–178. doi:10.1200/JCO.2010.33.7089.; Burdett S., Stewart L., Auperin A., Pignon J.P. Chemotherapy in non–small-cell lung cancer: an update of an individual patient data metaanalysis. J Clin Oncol. 2005; (23):924–925. author reply 925-926. doi:10.1200/JCO.2008.17.7162.; Garon E.B., Hellmann M.D., Costa E.C., et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. J Clin Oncol. 2019 (suppl; abstr LBA9015). doi:10.1200/JCO.2019.37.18_suppl.LBA9015.; Brahmer J., Borghaei H., Ramalingam S.S., Horn L., Holgado E., Pluzanski A., Burgioet M. et al. Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response. Conference: Proceedings: AACR Annual Meeting. 2019; March 29-April 3, 2019; Atlanta, GA. doi:10.1158/1538-7445.AM2019-CT195.; Horn L., Gettinger S., Gordon M., Herbst R., Gandhi L., Felip E. et al. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal of Cancer. 2018;(101):201-209. doi:10.1016/j.ejca.2018.06.031.; Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012.; Rusch V., Chaft J., Johnson B., Wistuba I., Kris M., Lee J. et al. Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3). Journal of Clinical Oncology. 2018;36(15_suppl):8541-8541. doi:10.1200/JCO.2018.36.15_suppl.8541.; Cascone T., William W.N., Weissferdt A., Leung C.H., Federico L., Haymaker C. et al. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol. 2019;(37S):ASCO#8504. doi:10.1200/JCO.2019.37.15_suppl.8504.; Forde P.M., Chaft J.E., Smith K.N., Anagnostou V., Cottrell T., Hellmann M., Zahurak M., Yang S. et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-1986. doi:10.1056/NEJMoa1716078.; Chaft J.E., Rusch V., Ginsberg M.S., Paik P.K., Finley D.J., Kris M.G., et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 2013;8(8):1084-1090. doi:10.1097/JTO.0b013e31829923ec.; Provencio M., Nadal E., Insa A., García Campelo R., Huidobro G., Domine M. et al. WCLC 2018 Abstract OA01.05. Available at: https://adisinsight.springer.com/trials/700281155.; Shu C., Grigg C., Chiuzan C., Garofano R., Patel V., Hernandezet S. et al. Neoadjuvant atezolizumab + chemotherapy in resectable nonsmall cell lung cancer (NSCLC). Journal of Clinical Oncology. 2018;36(15_suppl):8532-8532. doi:10.1200/JCO.2018.36.15_suppl.8532.; https://www.med-sovet.pro/jour/article/view/5047

الاتاحة: https://www.med-sovet.pro/jour/article/view/5047
https://doi.org/10.21518/2079-701X-2019-19-22-29

المؤلفون: K. Laktionov K., E. Reutova V., К. Лактионов К., Е. Реутова В.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2019); 37-41 ; Медицинский Совет; № 10 (2019); 37-41 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-10

مصطلحات موضوعية: ALK, non-small-cell lung cancer, ceritinib, немелкоклеточный рак легкого, церитиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3051/2975; Клинические рекомендации АОР по терапии рака легкого http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf. [AOR clinical guidelines for the lung cancer treatment http://oncology-association.ru/files/clinical-guidelines_adults/rak_legkogo.pdf.] (In Russ).; Santarpia M., Daffinà M.G., D’Aveni A. et al. Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy. Drug Design, Development and Therapy, 2017.; Kim D.W., Mehra R., Tan D.S.W. et al. Activity and safety of ceritinib in patients with ALKrearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452-463.; Preusser M., Winkler F., Valiente M., et al. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO Open. 2018;3:e000262. doi:10.1136/esmoopen-2017-000262.; Katayama R., Khan T.M., Benes C., et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011;108(18):7535-7540.; Friboulet L., Li N., Katayama R. et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014 June;4(6):662–673.; Felip E., Nishio M., Orlov S. et al. Phase II study of ceritinib in ALK inhibitor (ALKi)- naïve patients with ALK-rearranged nonsmall cell lung cancer: final efficacy and safety results from ASCEND-3. ESMO. 2018;abstract LBA57.; Felip E., Orlov S., Park K. et al. Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK +) non-small cell lung cancer (NSCLC): whole body responses in the overall pt group and in pts with baseline brain metastases (BM). Ann Oncol. 2016;27(suppl 6):416-454.; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-broadens-ceritinibindication-previously-untreated-alk-positivemetastatic-nsclc.; Soria J.C., Tan D.S., Chiari R., et al: First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): A randomised, openlabel, phase 3 study. Lancet. 2017;389:917-929.; Shaw A.T., Kim T.M., Crinò L. et al. ASCEND-5: a randomised, phase 3 study of ceritinib versus chemotherapy in adult patients with ALKrearranged non-small cell lung cancer, previously treated with chemotherapy and crizotinib. Lancet Oncol. 2017;18:874–886.; GLEEVEC (imatinib mesylate) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2001.; Abbas R., Hug B.A., Leister C., Gaaloul M.E., Chalon S., and Sonnichsen D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol. 2012;69:221–227.; Lau Y.Y., Gu W., Lin T., Song D., Yu R., and Scott J.W. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. J Clin Pharmacol. 2016;56:559–566.; Cho B.C., Kim D.W., Bearz A. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 2017;12(Issue 9):1357–1367.; Cho B.C., Obermannova R., Bearz A. et al. Efficacy and Safety of Ceritinib (450 mg/day or 600 mg/day) With Food vs 750 mg/day Fasted in Patients With ALK-Positive NSCLC: Primary Efficacy Results From ASCEND-8 Study. J Thorac Oncol. 2019 Mar 6;pii: S1556-0864(19)30195-9.; https://www.med-sovet.pro/jour/article/view/3051

الاتاحة: https://www.med-sovet.pro/jour/article/view/3051
https://doi.org/10.21518/2079-701X-2019-10-37-41

المؤلفون: K. Laktionov K., D. Yudin I., K. Sarantseva A., K. Laktionov P., V. Breder V., E. Reutova V., К. Лактионов К., Д. Юдин И., К. Саранцева А., К. Лактионов П., В. Бредер В., Е. Реутова В.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2018); 9-10 ; Медицинский Совет; № 10 (2018); 9-10 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-10

مصطلحات موضوعية: pemribrolizumab, non-small cell lung cancer, PD-1, PD-L1, пембролизумаб, немелкоклеточный рак легкого

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2526/2494; Лактионов К.К., Саранцева К.А., Бредер В.В., Окружнова М.А., Перегудова М.В. Место иммуноонкологии в лечении немелкоклеточного рака легкого. Злокачественные опухоли, 2016, 3: 17-24.; Саранцева К.А., Лактионова Л.В., Реутова Е.В., Черненко П.А., Бредер В.В. Иммунология: формирование иммунного ответа как ведущего фактора противоопухолевой защиты. Злокачественные опухоли, 2016, 2: 5-13.; Bonomi P. Implications of key trials in advanced nonsmall cell lung cancer. Cancer, 2010, 116: 1155-64.; Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–smallcell lung cancer. N Engl J Med, 2016, 375(19): 1823-33.; Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355: 2524-50.; Scagliotti G, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy naïve patients with advanced-stage nonsmall-cell lung cancer. J Clin Oncol, 2008, 26: 3543-51.; Herbst R et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016 Apr 9, 387(10027): 1540-50. doi:10.1016/S0140-6736(15)01281-7.; Shaverdian N, Lisberg A, Bornazyan K et al. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol, 2017. Published Online May 24, 2017. doi:10.1016/S1470-2045(17)30380-7.; Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 2015, 372: 2018-28.; Leighl N, Hellmann M, Hui R et al. KEYNOTE-001: 3-year overall survival for patients with advanced NSCLC treated with pembrolizumab. Journal of Clinical Oncology, 2017 May, 35(15_suppl): 9011-9011. doi:10.1200/JCO.2017.35.15_suppl.9011.; Chae YK, Pan A, Davis AA, Raparia K et al. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection? Clin. Lung Cancer., 2016, 17(5): 350-361.; Brahmer JR, Rodríguez-AbreuD, Robinson AG, Hui, R et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-based Chemotherapy for Advanced NSCLC With PD-L1 TPS ≥50%. Journal of Thoracic Oncology, 2017 Nov, 12(11): 1793-1794.; https://www.med-sovet.pro/jour/article/view/2526

الاتاحة: https://www.med-sovet.pro/jour/article/view/2526
https://doi.org/10.21518/2079-701X-2018-10-9-10

المؤلفون: L. Nelyubina A., E. Reutova V., K. Laktionov K., D. Yudin I., D. Marinov T., E. Kozak N., V. Mochalnikova V., Л. Нелюбина А., Е. Реутова В., К. Лактионов К., Д. Юдин И., Д. Маринов Т., Е. Козак Н., В. Мочальникова В.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2018); 130-135 ; Медицинский Совет; № 19 (2018); 130-135 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-19

مصطلحات موضوعية: non-small cell lung cancer, activating mutations, EGFR, small cell cancer, EGFR tyrosine kinase inhibitors, resistance, rebiopsy, немелкоклеточный рак легкого, активирующие мутации, мелкоклеточный рак, ингибиторы тирозинкиназ EGFR, резистентность, ребиопсия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2761/2713; Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive nonsmall-cell lung cancer (EU_ RTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246.; Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013, 31: 3327-3334.; Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13: 239-246.; Nishino M, Cardarella S, Jackman DM et al. RECIST 1.1 in NSLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0. AJR Am J Roentgenol, 2013, 201: W64-71.; Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361: 947-957.; Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer. N Engl J Med, 2017, 376: 629-640.; Riely GJ, Yu HA. EGFR: the paradigm of an oncogene-driven lung cancer. Clin Cancer Res, 2015, 21: 2221-2226.; Yu PP, Vose JM, Hayes DF. Genetic cancer susceptibility testing: increased technology, increased complexity. J Clin Oncol, 2015, 33: 3533-3534.; Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res, 2013, 19: 2240-2247.; Finlay MR, Anderton M, Ashton S, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem, 2014, 57: 8249-8267.; Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol, 2013, 31: 3987-3996.; Onitsuka T, Uramoto H, Nose N, et al. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer, 2010, 68: 198-203.; Lfnger CJ. Epidermal growth factor receptor inhibition in mutation-positive non-small-cell lung cancer: is afatinib better or simply newer? J Clin Oncol, 2013, 31: 3303-3306.; Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011 Mar 23, 3(75): 75ra26.; Thomson S, Buck E, Petti F, Griffin G et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res, 2005 Oct 15, 65(20): 9455-62.; Qiuxiang Ou, Xue Wu, Hua Bao et al. Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing. J Clin Oncol, 2017, suppl 2572.; https://www.med-sovet.pro/jour/article/view/2761

الاتاحة: https://www.med-sovet.pro/jour/article/view/2761
https://doi.org/10.21518/2079-701X-2018-19-130-135

المؤلفون: Е. Реутова В., К. Лактионов К., М. Ардзинба С., Л. Нелюбина А., А. Арзуманян Л.

المصدر: Meditsinskiy sovet = Medical Council; № 14 (2017); 24-28 ; Медицинский Совет; № 14 (2017); 24-28 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-14

مصطلحات موضوعية: non-small cell lung cancer, EGFR, tyrosine kinase inhibitors of EGFR, resistance, osimertinib, немелкоклеточный рак легкого, ингибиторы тирозинкиназы EGFR, резистентность, осимертиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2164/2147; Тюляндин С.А., Имянитов Е.Н., Моисеенко В.М., Пономаренко Д.М., Гурина Л.И., Королева И.А., Карасева В.В. Терапия больных немелкоклеточным раком легкого в Российской Федерации: исследование EPICLIN-Lung. Современная онкология, 2016, 04: 27-33.; Antonicelli A, Cafarotti S, Indini A et al. EGFRtargeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci, 2013, 10: 320-330.; Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.; Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT et al. First-SIGNAL: first-line single-agent iressa versus gemcitabineand cisplatin trial in neversmokers with adenocarcinoma of the lung. J Clin Oncol, 2012, 30(10): 1122-1128.; Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S,Isobe H et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 2013, 24(1): 54-59.; Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.; Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients Management; of Adverse Events from EGFR Tyrosine Kinase Inhibitors 1347 with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.; Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.; Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-posi-tive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246.; Majem M, Remon J. Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients. Lung Cancer Res, 2013, 226-237.; Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol, 2012, 13: e23-31.; Rosell R, Molina MA, Costa C et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced nonsmall-cell lung cancer patients with EGFR mutations. Clin Cancer Res, 2011, 17: 1160-1168.; Rosell R, Molina-Vila MA, Taron M et al. EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study. J Clin Oncol, 2012, 30: abstr 7522.; Fujita Y, Suda K, Kimura H et al. Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol, 2012, 7: 1640-1644.; Girard N, Lou E, Azzoli CG et al. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clin Cancer Res, 2010, 16: 755-763.; Ikeda K, Nomori H, Mori T et al. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg, 2008, 85: 1430-1432.; Ohtsuka K, Ohnishi H, Kurai D et al. Familial lung adenocarcinoma caused by the EGFR V843I germline mutation. J Clin Oncol, 2011, 29: e191-192.; Jackman D, Pao W, Reily GJ et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in nonsmall-cell lung cancer. J. Clin. Oncol., 2010, 28: 357-360.; Gandara DR, Lara PN et al. Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. Clin. Lung Cancer, 2014, 15: 1-6.; Park K, Tsai C-M, Ahn M-J et al. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patient (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). J. Clin. Oncol., 2012, 30: A#TPS7614.; Mok TS, Kim SW, Wu YL et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive nonsmall-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analysis. J Clin Oncol, 2017 Oct 2. doi:10.1200/JCO.2017.73.9250.; Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362: 2380-2388.; Kobayashi S, Boggon TJ, Dayaram T et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med, 2005, 352: 786-792.; Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med, 2005, 2: e73.; Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene, 2009, 28: S24-31.; Oxnard GR, Arcila ME, Chmielecki J et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res, 2011, 17: 5530-5537.; Regales L, Gong Y, Shen R et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest, 2009, 119: 3000-3010.; Janjigian YY, Smit EF, Groen HJ et al. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov, 2014, 4: 1036-1045.; Mok TS, Wu Y-L, Ahn M-J et al. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung. Cancer N Engl J Med, 2017, 376: 629-640.; Ramalingam S.S., Yang JC-H, Chee Khoon Lee. Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung. Cancer J Clin Oncol, 35. Aug2017.; Niederst MJ, Hu H, Mulvey HE et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res, 2015, 21: 3924-3933.; Lovly CM. ASCO EDUCATIONAL BOOK, 2015: e165-173.; Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 2011, 3: 75ra26.; Takezawa K, Pirazzoli V, Arcila ME et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFRmutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov, 2012, 2: 922-933.; Pao W, Wang TY, Riely GJ et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005, 2: e17.; Ohashi K, Sequist LV, Arcila ME et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A, 2012, 109: E2127-2133.; Ercan D, Xu C, Yanagita M et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov, 2012, 2: 934-947.; Engelman JA, Mukohara T, Zejnullahu K et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFRamplified lung cancer. J Clin Invest, 2006, 116: 2695-2706.; Zhang Z, Lee JC, Lin L et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet, 2012, 44: 852-860.; Byers LA, Diao L, Wang J et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res, 2013, 19: 279-290.; Bivona TG, Hieronymus H, Parker J et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471: 523-6KDM5A.; Sharma SV, Lee DY, Li B et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 2010, 141: 69-80.; Brock A, Chang H, Huang S. Non-genetic heterogeneity-a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet, 2009, 10: 336-342.; Gupta PB, Fillmore CM, Jiang G et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell, 2011, 146: 633-644.; Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer, 2002, 2: 442-454. 46. Thomson S, Buck E, Petti F et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res, 2005, 65: 9455-9462.; Rho JK, Choi YJ, Lee JK et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer, 2009, 63: 219-226.; Suda K, Tomizawa K, Fujii M et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol, 2011, 6: 1152-1161.; Buonato JM, Lazzara MJ. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition. Cancer Res, 2014, 74: 309-319.; https://www.med-sovet.pro/jour/article/view/2164; undefined

الاتاحة: https://www.med-sovet.pro/jour/article/view/2164

المؤلفون: К. LAKTIONOV К., М. PEREGUDOVA V., V. BREDER V., E. REUTOVA V., D. PEREGUDOV A., M. ARDZINBA S., P. CHERNENKO A., D. MARINOV T., К. ЛАКТИОНОВ К., М. ПЕРЕГУДОВА В., В. БРЕДЕР В., Е. РЕУТОВА В., Д. ПЕРЕГУДОВ А., М. АРДЗИНБА С., П. ЧЕРНЕНКО А., Д. МАРИНОВ Т.

المصدر: Meditsinskiy sovet = Medical Council; № 10 (2016); 66-72 ; Медицинский Совет; № 10 (2016); 66-72 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2016-10

مصطلحات موضوعية: non-small-cell lung cancer, adenocarcinoma, EGFR mutation, Del19, L858R, afatinib, немелкоклеточный рак легкого, аденокарцинома, мутация гена EGFR, афатиниб

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1407/1365; Imyanitov EN, Demidova IA, Gordiev MG et al. Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. Molecular Diagnosis & Therapy, 2016 Aug, 20(4): 401-6.; Reguart N, Remon J. Common EGFR-mutated subgroups (Del19/L858R) in advanced nonsmall- cell lung cancer: chasing better outcomes with tyrosine-kinase inhibitors. 10.2217/ FON.15.15 © 2015 Future Medicine Ltd.; Mok T, Wu Y-L, Throngprasert S et al. Gefitinib or Carboplatin-Paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine, 2009, 361: 947-957.; Han JY, Park K, Kim SW et al. First-signal: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung; Journal of Clinical Oncology, 2012, 30:1122-8. doi:10.1200/JCO.2011.36.8456.; Mitsudomi T, Morita S, Yatabe Y et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factorreceptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncology, 2010, 11: 121-128.; Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for Non-Small-Cell lung cancer with mutated EGFR. The New England Journal of Medicine, 2010, 362: 2380- 2388.; Zhou C, Wu Y-L, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive nonsmall- cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology, 2011, 12: 735-742.; Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standart chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 2012, 13: 239-246.; Chih-Hsin Yang J et al. Afatinib versus cisplatin- based chemotherapy for EGFR mutationpositive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncology, 2015, 16(2): 141-151. DOI:10.1016/S1470-2045(14)71173-8.; Solca F, Dahl G, Zoephel A, Bader G , Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR. Target binding properties and cellular activity of afatinib (BBW 2992), in irreversible ErbB family blocker. J Pharmacol Exp Ther, 2012,343: 342-350.; Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene, 2008, 27: 4702-11.; Modjtahedi H et al. A comprehensive review of the preclinical efficacy profile of the ErbB familyblocker afatinib in cancer. Naunyn-Schmiedeberg’sArch Pharmacol, 2014, 387:505-521.; Горбунова В.А. Афатиниб – первый селективный необратимый ингибитор семейства ErbB. Эффективная Фармакотерапия. Онкология, гематология и радиология, 2014, 2(37): 20-28./ Gorbunova V.A. Afatinib is the first selective non-eversible nhibitor of ErbB family. Effektivnaya Farmakoterapia. Onkologia, Gematologia I Radiologia, 2014, 2(37): 20-28.; Sequist L, Chih-Hsin Yang J, Yamamoto N et al. Phase III study of afatinib or cisplatin pluspemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 2013, 31: 3327-3334.; Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for fi rst-line treatment of Asian patients with advanced nonsmall- cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014, 15: 213-22.; Keunchil Park, Eng-Huat Tan et al. Afatinib versus gefi tinib as fi rst-line treatment of patients with EGFR mutation-positive nonsmall-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomized controlled trial. Lancet Oncol, 2016, 17: 577-89.; Hall PE, Spicer J, Popat S. Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. Future Oncol, 2015, 11(15): 2175-2191.; Schuler M, Yang JC-H et al. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/ gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Annals of Oncology 00: 1-7, 2016. doi:10.1093/annonc/mdv597.; Онкология. Клинические рекомендации под редакцией академика РАН Давыдова М.И. Москва 2015./Oncology Clinical Recommendations ed. By Academician of RAS Davydov M.I.; «Федеральные клинические рекомендации по диагностике и лечению больных раком легкого». Ассоциация онкологов России. Москва 2014г. http://www.oncology.ru/association/ clinical-guidelines/2014/small-cell-lungcancer/. Federal Clinical Recommendations on Diagnostics and Therapy of Pulmonary Cancer. Russian Oncologist Association. Moscow 2014. http://www.oncology.ru/association/clinicalguidelines/ 2014/small-cell-lung-cancer/; NCCN Clinical Practice Guidelines in Oncology “Non-Small Cell Lung Cancer. Version 4.2016. http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf.; Reck M, Popat S et al. ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Ann Oncol, 2014, 25(suppl 3): iii27-iii39. http://www.esmo.org/Guidelines/Lung- ancer/ Metastatic-Non-Small-Cell-Lung-Cancer.; Masters GA, Temin S et al. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Published online ahead of print at www.jco.org on August 31, 2015. doi:10.1200/JCO.2014.60.6624 Clin Oncol, 33. © 2015 by American Society of Clinical Oncology.; https://www.med-sovet.pro/jour/article/view/1407

الاتاحة: https://www.med-sovet.pro/jour/article/view/1407
https://doi.org/10.21518/2079-701X-2016-10-66-72